Multicentric Analysis of the Species Distribution and Antifungal Susceptibility of Cryptic Isolates from Aspergillus Section Fumigati

The antifungal susceptibility of Aspergillus cryptic species is poorly known. We assessed 51 isolates, belonging to seven Fumigati cryptic species, by the EUCAST reference method and the concentration gradient strip (CGS) method. Species-specific patterns were observed, with high MICs for azole drugs, except for Aspergillus hiratsukae and Aspergillus tsurutae, and high MICs for amphotericin B for Aspergillus lentulus and Aspergillus udagawae. ABSTRACT The antifungal susceptibility of Aspergillus cryptic species is poorly known. We assessed 51 isolates, belonging to seven Fumigati cryptic species, by the EUCAST reference method and the concentration gradient strip (CGS) method. Species-specific patterns were observed, with high MICs for azole drugs, except for Aspergillus hiratsukae and Aspergillus tsurutae, and high MICs for amphotericin B for Aspergillus lentulus and Aspergillus udagawae. Essential and categorical agreements between EUCAST and CGS results were between 53.3 and 93.3%.

[1]  S. Ranque,et al.  Species Distribution and Comparison between EUCAST and Gradient Concentration Strips Methods for Antifungal Susceptibility Testing of 112 Aspergillus Section Nigri Isolates , 2020, Antimicrobial Agents and Chemotherapy.

[2]  J. Frisvad,et al.  Classification of Aspergillus, Penicillium, Talaromyces and related genera (Eurotiales): An overview of families, genera, subgenera, sections, series and species , 2020, Studies in mycology.

[3]  N. Doucet,et al.  Prevalence and mechanisms of azole resistance in clinical isolates of Aspergillus section Fumigati species in a Canadian tertiary care centre, 2000 to 2013. , 2019, The Journal of antimicrobial chemotherapy.

[4]  C. Hennequin,et al.  Comparison of the MICs Obtained by Gradient Concentration Strip and EUCAST Methods for Four Azole Drugs and Amphotericin B against Azole-Susceptible and -Resistant Aspergillus Section Fumigati Clinical Isolates , 2019, Antimicrobial Agents and Chemotherapy.

[5]  R. Piarroux,et al.  Multi-centric evaluation of the online MSI platform for the identification of cryptic and rare species of Aspergillus by MALDI-TOF. , 2019, Medical mycology.

[6]  J. Frisvad,et al.  cyp51A Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex , 2019, Antimicrobial Agents and Chemotherapy.

[7]  É. Fournier,et al.  Draft Genome Sequence of Azole-Resistant Aspergillus thermomutatus (Neosartorya pseudofischeri) Strain HMR-AF-39, Isolated from a Human Nasal Septum Abscess Aspirate , 2019, Microbiology Resource Announcements.

[8]  T. Peláez,et al.  Molecular Identification and Susceptibility Testing of Molds Isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 Study) , 2018, Antimicrobial Agents and Chemotherapy.

[9]  P. Hamal,et al.  Antifungal Susceptibility of the Aspergillus viridinutans Complex: Comparison of Two In Vitro Methods , 2018, Antimicrobial Agents and Chemotherapy.

[10]  S. Ranque,et al.  Validation of a New Web Application for Identification of Fungi by Use of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry , 2017, Journal of Clinical Microbiology.

[11]  S. Ranque,et al.  Previously unknown species of Aspergillus. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  F. Lamoth.  Aspergillus fumigatus-Related Species in Clinical Practice , 2016, Front. Microbiol..

[13]  A. Colombo,et al.  Cryptic and Rare Aspergillus Species in Brazil: Prevalence in Clinical Samples and In Vitro Susceptibility to Triazoles , 2014, Journal of Clinical Microbiology.

[14]  J. Varga,et al.  Phylogeny, identification and nomenclature of the genus Aspergillus , 2014, Studies in mycology.

[15]  A. Roden,et al.  Misidentification of Neosartorya pseudofischeri as Aspergillus fumigatus in a Lung Transplant Patient , 2014, Journal of Clinical Microbiology.

[16]  J. Melichar,et al.  Rare and new etiological agents revealed among 178 clinical Aspergillus strains obtained from Czech patients and characterized by molecular sequencing. , 2012, Medical mycology.

[17]  L. Mély,et al.  Unusual Aspergillus species in patients with cystic fibrosis. , 2010, Medical mycology.

[18]  C. Bonnal,et al.  Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  B. Alexander,et al.  Molecular Identification of Aspergillus Species Collected for the Transplant-Associated Infection Surveillance Network , 2009, Journal of Clinical Microbiology.

[20]  E. Mellado,et al.  Aspergillus Section Fumigati: Antifungal Susceptibility Patterns and Sequence-Based Identification , 2008, Antimicrobial Agents and Chemotherapy.

[21]  D. Denning,et al.  EUCAST DEFINITIVE DOCUMENT E.DEF 9.1: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds , 2008 .

[22]  P. Nielsen,et al.  New taxa of Neosartorya and Aspergillus in Aspergillus section Fumigati , 2007, Antonie van Leeuwenhoek.

[23]  D. Nickle,et al.  Molecular Studies Reveal Frequent Misidentification of Aspergillus fumigatus by Morphotyping , 2006, Eukaryotic Cell.

[24]  D. Nickle,et al.  Aspergillus lentulus sp. nov., a New Sibling Species of A. fumigatus , 2005, Eukaryotic Cell.